Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C K Lin

Showing results (221-230 of 235) with videos related to

Pageof 24
Sort By:
Vox Sanguinis|July 9, 2002
Prevention of post-transfusion cytomegalovirus: leucoreduction or screening?H W Reesink, C P Engelfriet, G E Tegtmeier, et al.
Vox Sanguinis|June 26, 2003
The future use of pathogen-inactivated platelet concentratesC P Engelfriet, H W Reesink, H G Klein, et al.
Vox Sanguinis|August 20, 2003
Future counselling of donors and recipients of blood products concerning prion-related diseasesH W Reesink, C P Engelfriet, L Muylle, et al.
Vox Sanguinis|February 16, 2013
The use of the electronic (computer) cross-matchH W Reesink, K Davis, J Wong, et al.
Vox Sanguinis|July 14, 2001
The use of the computer cross-matchC P Engelfreit, H W Reesink, T Krusius, et al.
Vox Sanguinis|February 24, 2001
Quality assurance, quality control and accreditationC P Engelfriet, H W Reesink, G G de Lange, et al.
Vox Sanguinis|May 10, 2005
Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003J Coste, H W Reesink, C P Engelfriet, et al.
Vox Sanguinis|March 25, 2014
Bacterial contamination in platelet concentratesR N I Pietersz, H W Reesink, S Panzer, et al.
Vox Sanguinis|January 6, 2009
Donors with a rare pheno (geno) typeH W Reesink, C P Engelfriet, H Schennach, et al.
Vox Sanguinis|October 14, 2011
Deferral of males who had sex with other malesR J Benjamin, C Bianco, M Goldman, et al.
Pageof 24

Showing results (221-230 of 235) with videos related to

Sort By:
Pageof 24
Vox Sanguinis|July 9, 2002
Prevention of post-transfusion cytomegalovirus: leucoreduction or screening?H W Reesink, C P Engelfriet, G E Tegtmeier, et al.
Vox Sanguinis|June 26, 2003
The future use of pathogen-inactivated platelet concentratesC P Engelfriet, H W Reesink, H G Klein, et al.
Vox Sanguinis|August 20, 2003
Future counselling of donors and recipients of blood products concerning prion-related diseasesH W Reesink, C P Engelfriet, L Muylle, et al.
Vox Sanguinis|February 16, 2013
The use of the electronic (computer) cross-matchH W Reesink, K Davis, J Wong, et al.
Vox Sanguinis|July 14, 2001
The use of the computer cross-matchC P Engelfreit, H W Reesink, T Krusius, et al.
Vox Sanguinis|February 24, 2001
Quality assurance, quality control and accreditationC P Engelfriet, H W Reesink, G G de Lange, et al.
Vox Sanguinis|May 10, 2005
Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003J Coste, H W Reesink, C P Engelfriet, et al.
Vox Sanguinis|March 25, 2014
Bacterial contamination in platelet concentratesR N I Pietersz, H W Reesink, S Panzer, et al.
Vox Sanguinis|January 6, 2009
Donors with a rare pheno (geno) typeH W Reesink, C P Engelfriet, H Schennach, et al.
Vox Sanguinis|October 14, 2011
Deferral of males who had sex with other malesR J Benjamin, C Bianco, M Goldman, et al.
Pageof 24